Your browser is no longer supported. Please, upgrade your browser.
DCPH Deciphera Pharmaceuticals, Inc. daily Stock Chart
DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.15 Insider Own0.60% Shs Outstand55.92M Perf Week8.74%
Market Cap3.58B Forward P/E- EPS next Y-4.47 Insider Trans-51.64% Shs Float39.76M Perf Month33.35%
Income-263.50M PEG- EPS next Q-1.30 Inst Own76.80% Short Float10.52% Perf Quarter30.10%
Sales7.20M P/S497.18 EPS this Y-58.90% Inst Trans0.29% Short Ratio11.57 Perf Half Y32.36%
Book/sh11.08 P/B5.78 EPS next Y14.40% ROA-39.20% Target Price73.00 Perf Year80.99%
Cash/sh10.92 P/C5.87 EPS next 5Y21.00% ROE-43.10% 52W Range33.10 - 71.11 Perf YTD2.92%
Dividend- P/FCF- EPS past 5Y- ROI-36.70% 52W High-9.91% Beta-
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin99.90% 52W Low93.53% ATR2.94
Employees255 Current Ratio12.30 Sales Q/Q-71.60% Oper. Margin- RSI (14)73.76 Volatility4.64% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-114.00% Profit Margin- Rel Volume0.59 Prev Close63.49
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume361.54K Price64.06
Recom1.90 SMA2015.55% SMA5027.08% SMA20021.27% Volume213,120 Change0.90%
Sep-14-20Resumed JP Morgan Neutral $52
May-07-20Downgrade Nomura Buy → Neutral $84 → $60
Mar-04-20Initiated Barclays Overweight $70
Dec-20-19Reiterated Jefferies Buy $53 → $77
Oct-29-19Upgrade SVB Leerink Underperform → Mkt Perform $29 → $34
Oct-22-19Initiated JMP Securities Mkt Outperform
Oct-03-19Initiated H.C. Wainwright Buy $60
Sep-30-19Initiated Jefferies Buy $47
Jul-18-19Initiated Deutsche Bank Buy $42
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Aug-29-18Initiated Raymond James Outperform $47
Jul-05-18Initiated SunTrust Buy
Jun-19-18Downgrade B. Riley FBR, Inc. Buy → Neutral $43
Feb-16-18Initiated B. Riley FBR, Inc. Buy $43
Oct-23-17Initiated Piper Jaffray Overweight $35
Oct-23-17Initiated Nomura Buy
Oct-23-17Initiated JP Morgan Overweight $30
Oct-23-17Initiated JMP Securities Mkt Outperform $38
Sep-22-20 04:23PM  
Sep-20-20 09:12AM  
Sep-18-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:48AM  
Aug-17-20 04:30PM  
Aug-06-20 08:40AM  
Aug-05-20 08:01AM  
Aug-04-20 06:25PM  
04:05PM  
Jul-29-20 07:00AM  
Jul-20-20 10:39AM  
07:30AM  
Jul-14-20 07:00AM  
Jul-12-20 08:15PM  
Jul-09-20 08:01AM  
Jul-02-20 04:01PM  
Jun-22-20 07:00AM  
Jun-17-20 07:36PM  
Jun-11-20 07:00AM  
Jun-08-20 07:30AM  
02:56AM  
Jun-03-20 07:11AM  
May-29-20 08:05AM  
08:00AM  
May-27-20 07:00AM  
May-26-20 07:06AM  
May-23-20 07:34AM  
May-18-20 04:16PM  
12:22PM  
06:15AM  
May-15-20 06:34PM  
May-12-20 06:53AM  
May-08-20 09:25AM  
May-06-20 12:01PM  
May-05-20 06:35PM  
04:01PM  
May-04-20 01:36PM  
08:45AM  
Apr-28-20 11:19AM  
07:00AM  
Apr-23-20 09:06AM  
Mar-28-20 09:10PM  
Mar-09-20 05:15PM  
04:01PM  
02:30PM  
Mar-02-20 07:00AM  
Feb-20-20 07:00AM  
Feb-19-20 04:01PM  
Feb-13-20 10:12PM  
01:36PM  
10:31AM  
08:05AM  
Feb-12-20 04:14PM  
04:01PM  
Jan-13-20 09:00AM  
Jan-11-20 06:09PM  
Jan-06-20 07:00AM  
Jan-02-20 06:40AM  
Dec-17-19 07:56AM  
Dec-16-19 07:00AM  
Dec-05-19 03:47PM  
Dec-04-19 04:05PM  
Nov-26-19 07:00AM  
07:00AM  
Nov-22-19 08:00PM  
Nov-13-19 04:30PM  
07:00AM  
Nov-04-19 05:15PM  
04:01PM  
Nov-01-19 10:24AM  
Oct-30-19 10:15AM  
Oct-29-19 12:30PM  
07:32AM  
Oct-28-19 06:06PM  
12:30PM  
07:00AM  
Oct-17-19 10:21AM  
Oct-16-19 04:34PM  
Oct-15-19 05:07PM  
Oct-04-19 09:00AM  
05:56AM  
Oct-02-19 07:00AM  
Sep-30-19 09:06AM  
Sep-25-19 07:00AM  
Sep-03-19 04:01PM  
Aug-20-19 07:15AM  
Aug-19-19 04:01PM  
Aug-15-19 07:45AM  
Aug-14-19 10:43PM  
04:28PM  
09:37AM  
Aug-13-19 06:02PM  
04:31PM  
04:10PM  
04:01PM  
01:57PM  
12:55PM  
12:46PM  
12:28PM  
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bristol James ArthurDirectorOct 09Option Exercise1.8923,54144,49223,541Oct 13 04:20 PM
Bristol James ArthurDirectorOct 09Sale53.5723,5411,261,0690Oct 13 04:20 PM
Taylor Michael DouglasDirectorOct 01Option Exercise1.89125,000236,250125,000Oct 05 04:00 PM
Taylor Michael DouglasDirectorOct 01Sale51.60125,0006,450,4840Oct 05 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Option Exercise1.893,0005,67010,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Sale50.013,000150,0367,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Option Exercise1.893,0005,67010,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Sale47.713,000143,1267,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Option Exercise1.896,00011,34013,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Sale45.496,000272,9297,040Sep 10 08:29 PM
Hoerter Steven L.President and CEOAug 20Option Exercise25.401874,75042,767Aug 24 04:00 PM
Flynn Daniel LeeChief Scientific OfficerAug 10Option Exercise1.899,02917,065237,475Aug 12 04:00 PM
Flynn Daniel LeeChief Scientific OfficerJul 22Option Exercise1.89130,000245,700228,446Jul 24 04:00 PM
Hoerter Steven L.President and CEOJul 20Option Exercise25.401884,77542,580Jul 22 04:00 PM
Bristol James ArthurDirectorJul 09Option Exercise1.8923,54144,49223,541Jul 13 04:11 PM
Bristol James ArthurDirectorJul 09Sale54.9923,5411,294,6340Jul 13 04:11 PM
Taylor Michael DouglasDirectorJul 06Option Exercise1.8927,54452,05827,544Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 06Sale55.2227,5441,520,8730Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Option Exercise1.8948,24591,18348,245Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Sale56.6948,2452,734,9650Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Option Exercise1.8949,21193,00949,211Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Sale58.8749,2112,896,8890Jul 06 06:16 PM
Hoerter Steven L.President and CEOJun 18Option Exercise25.401874,75042,392Jun 19 04:00 PM
Allen Patricia LDirectorJun 05Option Exercise25.735,635144,9895,635Jun 05 04:05 PM
Allen Patricia LDirectorJun 05Sale55.905,635314,9990Jun 05 04:05 PM
Allen Patricia LDirectorJun 03Option Exercise25.736,365163,7716,365Jun 05 04:05 PM
Allen Patricia LDirectorJun 03Sale59.146,365376,4500Jun 05 04:05 PM
Hoerter Steven L.President and CEOMay 28Option Exercise25.401884,77542,205Jun 01 04:05 PM
Kelly Thomas PatrickChief Financial OfficerMay 11Option Exercise1.8912,00022,68019,040May 13 04:05 PM
Kelly Thomas PatrickChief Financial OfficerMay 11Sale55.1912,000662,2407,040May 13 04:05 PM
Taylor Michael DouglasDirectorApr 28Option Exercise1.8925,00047,25025,000Apr 30 04:05 PM
Taylor Michael DouglasDirectorApr 28Sale56.9025,0001,422,4900Apr 30 04:05 PM
Hoerter Steven L.President and CEOApr 21Option Exercise25.401874,75042,017Apr 23 04:10 PM
Taylor Michael DouglasDirectorApr 17Option Exercise1.8923,89245,15623,892Apr 21 04:05 PM
Taylor Michael DouglasDirectorApr 17Sale46.6723,8921,115,1500Apr 21 04:05 PM
Taylor Michael DouglasDirectorApr 14Option Exercise1.891,1082,0941,108Apr 16 04:05 PM
Taylor Michael DouglasDirectorApr 14Sale46.711,10851,7530Apr 16 04:05 PM
Bristol James ArthurDirectorApr 09Option Exercise1.8923,54244,49423,542Apr 13 07:47 PM
Bristol James ArthurDirectorApr 09Sale43.8323,5421,031,8400Apr 13 07:47 PM
Taylor Michael DouglasDirectorApr 01Option Exercise1.8975,000141,75075,000Apr 03 04:10 PM
Taylor Michael DouglasDirectorApr 01Sale37.5775,0002,817,5580Apr 03 04:10 PM
Hoerter Steven L.President and CEOMar 18Option Exercise25.402,25057,15054,250Mar 20 05:49 PM
Allen Patricia LDirectorJan 24Sale66.1325,0001,653,3250Jan 28 04:13 PM
Martin Daniel C.Chief Commercial OfficerJan 22Option Exercise36.1026,999974,66443,999Jan 24 04:10 PM
Martin Daniel C.Chief Commercial OfficerJan 22Sale67.1826,9991,813,70917,000Jan 24 04:10 PM
Morl Christopher JohnChief Business OfficerJan 16Option Exercise3.953,01111,8933,011Jan 17 04:10 PM
Flynn Daniel LeeChief Scientific OfficerJan 16Option Exercise5.8066,906388,10391,406Jan 21 04:11 PM
Morl Christopher JohnChief Business OfficerJan 16Sale65.403,011196,9320Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 15Option Exercise3.9512,02347,49112,023Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 15Sale65.2312,023784,2740Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 08Option Exercise3.9512,28148,51012,281Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 08Sale60.1212,281738,2720Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 07Option Exercise3.951,6506,5181,650Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 07Sale60.021,65099,0350Jan 09 04:10 PM
Taylor Michael DouglasDirectorJan 03Option Exercise1.8931,42259,38831,422Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 03Option Exercise1.894,3598,2394,359Jan 06 04:15 PM
Bristol James ArthurDirectorJan 03Option Exercise1.897,98915,0997,989Jan 06 04:15 PM
Bristol James ArthurDirectorJan 03Sale57.357,989458,1950Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 03Sale57.354,359249,9930Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 03Sale57.3131,4221,800,9230Jan 06 04:15 PM
Morl Christopher JohnChief Business OfficerJan 02Option Exercise3.9516,13763,74116,137Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 02Option Exercise1.8993,578176,86293,578Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 02Option Exercise1.897,64114,4417,641Jan 06 04:15 PM
Bristol James ArthurDirectorJan 02Option Exercise1.8915,55329,39515,553Jan 06 04:15 PM
Bristol James ArthurDirectorJan 02Sale57.8315,553899,4680Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 02Sale57.817,641441,7480Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 02Sale57.8593,5785,413,1130Jan 06 04:15 PM
Morl Christopher JohnChief Business OfficerJan 02Sale58.5516,137944,8720Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerDec 23Option Exercise1.8940,00075,60040,000Dec 26 04:05 PM
Kelly Thomas PatrickChief Financial OfficerDec 23Sale68.2140,0002,728,3680Dec 26 04:05 PM
Morl Christopher JohnChief Business OfficerDec 12Option Exercise3.9515,03459,38415,034Dec 13 05:00 PM
Flynn Daniel LeeChief Scientific OfficerDec 12Sale60.0031,0291,861,74035,750Dec 13 05:00 PM
Morl Christopher JohnChief Business OfficerDec 12Sale60.0015,034902,0400Dec 13 05:00 PM
Morl Christopher JohnChief Business OfficerDec 10Option Exercise3.9511,64746,00611,647Dec 11 04:30 PM
Flynn Daniel LeeChief Scientific OfficerDec 10Option Exercise1.89122,752232,001118,430Dec 11 04:10 PM
Flynn Daniel LeeChief Scientific OfficerDec 10Sale55.00122,7526,751,36024,500Dec 11 04:10 PM
Morl Christopher JohnChief Business OfficerDec 10Sale55.0011,647640,5850Dec 11 04:30 PM
Morl Christopher JohnChief Business OfficerDec 09Option Exercise3.953,38713,3793,387Dec 11 04:30 PM
Flynn Daniel LeeChief Scientific OfficerDec 09Option Exercise1.8930,17557,03154,675Dec 11 04:10 PM
Flynn Daniel LeeChief Scientific OfficerDec 09Sale55.0030,1751,659,62524,500Dec 11 04:10 PM
Morl Christopher JohnChief Business OfficerDec 09Sale55.003,387186,2850Dec 11 04:30 PM
Morl Christopher JohnChief Business OfficerDec 03Option Exercise0.0015,034015,034Dec 05 04:20 PM
Morl Christopher JohnChief Business OfficerDec 03Sale50.0015,034751,7630Dec 05 04:20 PM
Flynn Daniel LeeChief Scientific OfficerNov 11Option Exercise1.89143,185270,620167,685Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 11Sale48.01143,1856,874,87024,500Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 08Option Exercise1.899,74218,41234,242Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 08Sale48.009,742467,61624,500Nov 13 04:59 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.